ANAB
AnaptysBioCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The bull case is that the completed spin removes structural uncertainty, leaves ANAB with a simpler royalty-management story, and eventually allows investors to value Jemperli and imsidolimab economics plus aggressive capital returns more cleanly once initial post-spin disclosures arrive [#8-K-2026-04-20] [#PR-2026-03-27].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -14.9.
What can break
Any underwhelming capital return execution could weaken the core standalone royalty-equity thesis.
Momentum
81
Value
41
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $56.00 · Bull $68.00 · Bear $38.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $81.50
Why
Momentum81 · Δ7d -14.9
Value41 · Δ7d +0.1
Sentiment47 · Δ7d +27.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
81
26% active weight
Current posture
7d trendSoftening
Δ7d
-14.9
Δ21d
-6.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
47
34% active weight
Current posture
7d trendImproving
Δ7d
+27.1
Δ21d
+21.0
Why this grade
Composite grade C. Momentum 80.7 / Value 41.1 / Sentiment 47.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$1.59B
Beta
0.36
Shares Out
29.61M
P/E (TTM) · Derived
-116.8
P/S (TTM)
7.06
P/FCF (TTM) · Derived
-452.52
Rev YoY
-8.0%
EPS YoY
+43.6%
Gross Margin
+99.0%
Op Margin
-16.9%
Net Debt
-$21M
Current Ratio
7.58
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology